Skip Navigation
ChemIDplus A TOXNET DATABASE LiteBrowseAdvanced

Substance Name: Cefsulodin sodium [USAN:JAN]
RN: 52152-93-9
UNII: 2D087186PY
InChIKey: REACMANCWHKJSM-DWBVFMGKSA-M

Note

  • A Pyridinium-substituted semisynthetic, broad-spectrum antibacterial used especially for Pseudomonas infections in debilitated patients.

Molecular Formulas

  • C22-H19-N4-Na-O8-S2
  • C22-H19-N4-O8-S2.Na
  • C22-H20-N4-O8-S2.Na

Molecular Weight

  • 554.5341
 

Classification Codes

  • Antibacterial
  • Drug / Therapeutic Agent
  • TSCA Flag PMN (a Commenced PMN (Premanufacture Notice) Substance)
* denotes mobile formatted website

Links to Resources

NLM Resources (File Locators)

Regulatory Agencies (Superlist Locators)

Other Resources (Internet Locators)


Search for this InChIKey on the Web

Names and Synonyms

Name of Substance

  • Cefsulodin sodium [USAN:JAN]

MeSH Heading

  • Cefsulodin

Synonyms

  • 4-Carbamoyl-1-(((6R,7R)-2-carboxy-8-oxo-7-((2R)-2-phenyl-2-sulfoacetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)pyridinium hydroxide, inner salt, monosodium salt
  • 4-Carbamoyl-1-(((6R,7R)-2-carboxy-8-oxo-7-((2R)-2-phenyl-2-sulfoacetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methylpyridinium hydroxide, inner salt, monosodium salt
  • Abbott 46811
  • Abbott-468 11
  • Abbott-46811
  • Cefomonil
  • Cefsulodin
  • Cefsulodin sodium
  • CGP 7174E
  • CGP-7174/E
  • EINECS 257-692-4
  • Monaspor
  • Pseudocef
  • Pseudomonil
  • Pyocefal
  • Pyridinium, 4-(aminocarbonyl)-1-((2-carboxy-8-oxo-7-((phenylsulfoacetyl)amino)-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, hydroxide, inner salt, monosodium salt, (6R-(6alpha,7beta(R*)))
  • SCE 129
  • Sulcephalosporin
  • Takesulin
  • Tilmapor
  • Ulfaret
  • UNII-2D087186PY

Systematic Names

  • Hydrogen (6R-(6alpha,7beta(R*)))-4-carbamoyl-1-((2-carboxylato-8-oxo-7-(phenylsulphonatoacetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)pyridinium, monosodium salt
  • Pyridinium, 4-(aminocarbonyl)-1-(((6R,7R)-2-carboxy-8-oxo-7-(((2R)-2-phenyl-2-sulfoacetyl)amino)-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, inner salt, sodium salt (1:1)
  • Pyridinium, 4-(aminocarbonyl)-1-(((6R,7R)-2-carboxy-8-oxo-7-(((2R)-phenylsulfoacetyl)amino)-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, inner salt, monosodium salt
  • Pyridinium, 4-(aminocarbonyl)-1-((2-carboxy-8-oxo-7-((phenylsulfoacetyl)amino)-5-thio-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, hydroxide, inner salt, monosodium salt, (6R-(6-alpha,7-beta(R*)))-

Registry Numbers

CAS Registry Number

  • 52152-93-9

FDA UNII

  • 2D087186PY

Related Registry Numbers

  • 52152-93-9 (mono-hydrochloride salt)
  • 52152-93-9 (Parent)

System Generated Number

  • 0052152939

Molecular Formulas

Molecular Formulas

  • C22-H19-N4-Na-O8-S2
  • C22-H19-N4-O8-S2.Na
  • C22-H20-N4-O8-S2.Na

Molecular Formula Fragments

  • C22-H19-N4-O8-S2
  • C22-H20-N4-O8-S2
  • COMPONENT
  • Na

Structure Descriptors

InChI

1S/C22H20N4O8S2.Na/c23-18(27)13-6-8-25(9-7-13)10-14-11-35-21-15(20(29)26(21)16(14)22(30)31)24-19(28)17(36(32,33)34)12-4-2-1-3-5-12;/h1-9,15,17,21H,10-11H2,(H4-,23,24,27,28,30,31,32,33,34);/q;+1/p-1/t15-,17-,21-;/m1./s1

InChIKey

REACMANCWHKJSM-DWBVFMGKSA-M

Smiles

[Na+].NC(=O)c1cc[n+](CC2=C(N3[C@H](SC2)[C@H](NC(=O)[C@@H](c4ccccc4)S(=O)(=O)[O-])C3=O)C(=O)[O-])cc1

Toxicity

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
dog LD50 oral > 15gm/kg (15000mg/kg)   Lyon Pharmaceutique. Vol. 34, Pg. 343, 1983.
dog LD50 parenteral > 2500mg/kg (2500mg/kg)   Lyon Pharmaceutique. Vol. 34, Pg. 343, 1983.
hamster LD50 intraperitoneal > 4gm/kg (4000mg/kg)   Lyon Pharmaceutique. Vol. 34, Pg. 343, 1983.
hamster LD50 oral > 15gm/kg (15000mg/kg)   Lyon Pharmaceutique. Vol. 34, Pg. 343, 1983.
hamster LD50 parenteral > 2500mg/kg (2500mg/kg)   Lyon Pharmaceutique. Vol. 34, Pg. 343, 1983.
mouse LD50 intramuscular 3800mg/kg (3800mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 12, Pg. 668, 1981.
mouse LD50 intraperitoneal 6350mg/kg (6350mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 12, Pg. 668, 1981.
mouse LD50 intravenous 3780mg/kg (3780mg/kg)   Drugs in Japan Vol. 6, Pg. 412, 1982.
mouse LD50 oral > 15gm/kg (15000mg/kg)   Lyon Pharmaceutique. Vol. 34, Pg. 343, 1983.
mouse LD50 parenteral > 2500mg/kg (2500mg/kg)   Lyon Pharmaceutique. Vol. 34, Pg. 343, 1983.
mouse LD50 subcutaneous 6940mg/kg (6940mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 12, Pg. 668, 1981.
rabbit LD50 oral > 15gm/kg (15000mg/kg)   Lyon Pharmaceutique. Vol. 34, Pg. 343, 1983.
rabbit LD50 parenteral > 2500mg/kg (2500mg/kg)   Lyon Pharmaceutique. Vol. 34, Pg. 343, 1983.
rat LD50 intramuscular 5530mg/kg (5530mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 12, Pg. 668, 1981.
rat LD50 intraperitoneal 3030mg/kg (3030mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 12, Pg. 668, 1981.
rat LD50 intravenous 3030ug/kg (3.03mg/kg)   Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 23, Pg. 439, 1981.
rat LD50 oral > 15gm/kg (15000mg/kg)   Lyon Pharmaceutique. Vol. 34, Pg. 343, 1983.
rat LD50 parenteral > 2500mg/kg (2500mg/kg)   Lyon Pharmaceutique. Vol. 34, Pg. 343, 1983.
rat LD50 subcutaneous 5550mg/kg (5550mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 12, Pg. 668, 1981.